Compare GPCR & MC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GPCR | MC |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Investment Managers |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.1B |
| IPO Year | 2023 | 2014 |
| Metric | GPCR | MC |
|---|---|---|
| Price | $16.13 | $51.35 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 11 |
| Target Price | ★ $104.86 | $65.70 |
| AVG Volume (30 Days) | 829.6K | ★ 938.0K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 4.86% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.75 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.60 |
| Revenue Next Year | N/A | $19.00 |
| P/E Ratio | ★ N/A | $71.36 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.88 | $51.06 |
| 52 Week High | $94.90 | $78.22 |
| Indicator | GPCR | MC |
|---|---|---|
| Relative Strength Index (RSI) | 22.78 | 32.85 |
| Support Level | N/A | $51.61 |
| Resistance Level | $22.54 | $70.99 |
| Average True Range (ATR) | 1.42 | 2.34 |
| MACD | 0.03 | -0.51 |
| Stochastic Oscillator | 1.14 | 1.23 |
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. It generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States, followed by Europe and the rest of the World.